Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Nisha De Silva"'
Autor:
Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Christian Maurer, Nisha De Silva, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens-Martin Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek, Barbara Eichhorst
Publikováno v:
HemaSphere, Vol 4, Iss 1, p e336 (2020)
Abstract. Fludarabine, cyclophosphamide and rituximab (FCR) was compared to bendamustine and rituximab (BR) in an international, randomized, open label, phase 3 trial in 561 previously untreated, fit patients with chronic lymphocytic leukemia (CLL) w
Externí odkaz:
https://doaj.org/article/9ab624e05ae342d4ae618cb2980e0b9d
Publikováno v:
HemaSphere, Vol 3, Iss 5 (2019)
Abstract. The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With long
Externí odkaz:
https://doaj.org/article/3d6c75a6427248eb806f4454a8591549
Autor:
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B.L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Publikováno v:
Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Nösslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jäger, U, Leys, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, J C, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, K A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S, Hallek, M, German CLL Study Group (GCLLSG), Haemato-Oncology Foundation for Adults in the Netherlands (HOVON), Nordic CLL Study Groups, Swiss Group for Clinical Cancer Research (SAKK), The Israeli CLL Association & Cancer Trials Ireland 2023, ' First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia ', The New England Journal of Medicine, vol. 388, no. 19, pp. 1739-1754 . https://doi.org/10.1056/NEJMoa2213093
BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57065540dd32adf0cc1d031449d13807
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e
Autor:
Michael Gregor, Florian Simon, Philipp B. Staber, Anna-Maria Fink, Christof Schneider, Vesa Lindström, Matthias Ritgen, Mels Hoogendoorn, Caspar da Cunha-Bang, Tamar Tadmor, Thomas Illmer, Maria B.L. Leijs, Arnon P. Kater, Nisha De Silva, Clemens-Martin Wendtner, Can Zhang, Julia von Tresckow, Marinus H. J. van Oers, Stephan Stilgenbauer, Henrik Frederiksen, Carsten Utoft Niemann, Moritz Fürstenau, Eugen Tausch, Michael Baumann, Sandra Robrecht, Christian Bjørn Poulsen, Ann Janssens, Holger Hebart, Monika Brüggemann, Gunnar Juliusson, Karl-Anton Kreuzer, Thomas Noesslinger, Tobias Gaska, Marjolein van der Klift, Christian H. Geisler, Kourosh Lotfi, Ilse Christiansen, Barbara Eichhorst, Björn Schöttker, Harry R. Koene, Mark-David Levin, Patrick Thornton, Michael Hallek, Kirsten Fischer, Ulrich Jaeger
Publikováno v:
Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Thomas Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U J, Frederiksen, H, B.L. Leijs, M, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Clemens-Martin Wendtner, Kreuzer, K-A, Ritgen, M, Brüggemann, M B, Tausch, E, Levin, M-D, van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Supplement 1, pp. 71 . https://doi.org/10.1182/blood-2021-146161
Eichhorst, B, Niemann, C, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Suppl. 1, 71 . https://doi.org/10.1182/blood-2021-146161
Eichhorst, B, Niemann, C, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Suppl. 1, 71 . https://doi.org/10.1182/blood-2021-146161
Background: For fit CLL patients (pts), continuous BTK inhibitor treatment is replacing CIT as standard of care in frontline setting, particularly in pts with unfavorable prognostic factors. The time limited combinations venetoclax plus obinutuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46700f17dedbd3070657cd5923f53a3a
https://portal.findresearcher.sdu.dk/da/publications/fca2ae81-daf7-4cd6-8e83-f4a2a71437b8
https://portal.findresearcher.sdu.dk/da/publications/fca2ae81-daf7-4cd6-8e83-f4a2a71437b8
Autor:
Nisha de Silva, F.
Publikováno v:
Disaster Prevention and Management: An International Journal, 2001, Vol. 10, Issue 1, pp. 11-20.
Externí odkaz:
http://www.emeraldinsight.com/doi/10.1108/09653560110381787
Autor:
Nisha De Silva, Barbara Eichhorst
Publikováno v:
Hematologic Malignancies ISBN: 9783030559885
With the increasing options of treatment in chronic lymphocytic leukemia (CLL), choice of optimal therapy in frontline and relapse has become a more complex process. While early stage and asymptomatic CLL should still undergo watch and wait, patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bda8774364ed92043107e7373ffc40a
https://doi.org/10.1007/978-3-030-55989-2_13
https://doi.org/10.1007/978-3-030-55989-2_13
Autor:
Anna-Maria Fink, Petra Langerbeins, Michael Hallek, Arnon P. Kater, Sandra Robrecht, Florian Simon, Thomas Illmer, Eugen Tausch, Stephan Stilgenbauer, Clemens M. Wendtner, Nisha De Silva, Moritz Fürstenau, Jolanda Droogendijk, Carsten Utoft Niemann, Kirsten Fischer, Björn Schöttker, Karin Hohloch, Michael Gregor, Marjolein van der Klift, Ellen van der Spek, Julia von Tresckow, Barbara Eichhorst
Publikováno v:
Leukemia
Leukemia, 34(8), 2225-2229. Nature Publishing Group
Fürstenau, M, Langerbeins, P, De Silva, N, Fink, A M, Robrecht, S, von Tresckow, J, Simon, F, Hohloch, K, Droogendijk, J, van der Klift, M, van der Spek, E, Illmer, T, Schöttker, B, Fischer, K, Wendtner, C M, Tausch, E, Stilgenbauer, S, Niemann, C U, Gregor, M, Kater, A P, Hallek, M & Eichhorst, B 2020, ' COVID-19 among fit patients with CLL treated with venetoclax-based combinations ', Leukemia, vol. 34, no. 8, pp. 2225-2229 . https://doi.org/10.1038/s41375-020-0941-7
Leukemia, 34(8), 2225-2229. Nature Publishing Group
Fürstenau, M, Langerbeins, P, De Silva, N, Fink, A M, Robrecht, S, von Tresckow, J, Simon, F, Hohloch, K, Droogendijk, J, van der Klift, M, van der Spek, E, Illmer, T, Schöttker, B, Fischer, K, Wendtner, C M, Tausch, E, Stilgenbauer, S, Niemann, C U, Gregor, M, Kater, A P, Hallek, M & Eichhorst, B 2020, ' COVID-19 among fit patients with CLL treated with venetoclax-based combinations ', Leukemia, vol. 34, no. 8, pp. 2225-2229 . https://doi.org/10.1038/s41375-020-0941-7
Autor:
Eugen Tausch, Mark-David Levin, Barbara Eichhorst, Tamar Tadmor, Sandra Robrecht, Thomas Illmer, Michael Hallek, Nisha De Silva, Monika Brüggemann, Clemens-Martin Wendtner, Moritz Fürstenau, Julia Von Tresckow, Stephan Stilgenbauer, Caspar da Cunha-Bang, Björn Schöttker, Arnon P. Kater, Christof Schneider, Michael Gregor, Philipp B. Staber, Florian Simon, Anna-Maria Fink, Michael Baumann, Ilse Christiansen, Can Zhang, Kirsten Fischer, Christian Bjørn Poulsen, Carsten Utoft Niemann, Patrick Thornton, Ann Janssens, Matthias Ritgen, Marinus H. J. van Oers, Thomas Noesslinger, Christian H. Geisler
Publikováno v:
Blood. 138:2639-2639
Background: In early studies of venetoclax (ven) in CLL, severe tumor lysis syndromes (TLS) were observed leading to the implementation of multiple safety measures including a 5-week ramp up schedule. Since then, studies have consistently reported lo
Autor:
Eugen Tausch, Barbara Eichhorst, Sandra Robrecht, Marinus H. J. van Oers, Nisha De Silva, Carsten Utoft Niemann, Monika Brüggemann, Patrick Thornton, Julia Von Tresckow, Arnon P. Kater, Caspar da Cunha-Bang, Philipp B. Staber, Anna-Maria Fink, Stephan Stilgenbauer, Can Zhang, Florian Simon, Christian H. Geisler, Matthias Ritgen, Michael Gregor, Kirsten Fischer, Mark-David Levin, Moritz Fürstenau, Michael Hallek, Anke Schilhabel, Clemens-Martin Wendtner, Tamar Tadmor
Publikováno v:
Blood. 138:72-72
Background: Venetoclax (ven)-based time-limited combination treatments have yielded high rates of undetectable MRD (uMRD) in patients (pts) with CLL. In correlative analyses, attainment of uMRD status was associated with longer progression-free survi
Publikováno v:
HemaSphere, Vol 3, Iss 5 (2019)
HemaSphere
HemaSphere
The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progres